Cravath’s London Office Moves to 100 Cheapside
Cravath has represented Johnson & Johnson in connection with the receipt by Ethicon Endo-Surgery, Inc. (“EES”), a Johnson & Johnson company, of an irrevocable, unconditional offer from Devicor Medical Products (“Devicor”), a portfolio company of private equity firm GTCR Golder Rauner, LLC (“GTCR”), to acquire EES’s Breast Care business. The EES Breast Care business sells products designed to help doctors diagnose breast cancer at early stages, while minimizing patient discomfort. The acceptance period for the offer will end on June 15, 2010, unless extended. If the offer is accepted by EES, the proposed transaction will be subject to the fulfillment of certain conditions and would be expected to close by the third quarter of 2010.
The Cravath team includes partner Robert I. Townsend III and associates Joseph D. Zavaglia and Namsun Kim on corporate matters; partner Eric W. Hilfers and associates Jarrett R. Hoffman and Jared R. Whalen on executive compensation and benefits matters; and partner Andrew W. Needham and associates J. Leonard Teti II and Matthew Cantor on tax matters.
Deals & Cases
March 12, 2025
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.